During the past decade, Clinique Saint-Pierre conducted 52 clinical trials. In the 10-year time frame, 52 clinical trials started and 20 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 15 clinical trials were completed. i.e. 57.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinique Saint-Pierre" #1 sponsor was "Cliniques universitaires Saint-Luc- Université Catholique de Louvain" with 11 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Celgene" with 5 trials sponsored, "The Lymphoma Academic Research Organisation" with 5 trials sponsored and "Eli Lilly and Company" with 5 trials sponsored. Other sponsors include 59 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinique Saint-Pierre" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Cliniques universitaires Saint-Luc- Université Catholique de Louvain" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Grand Hôpital de Charleroi" with 2 trials as a collaborator and "Hoffmann-La Roche" with 2 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Clinique Saint-Pierre" are "Breast Cancer" (9 trials), "Chronic Lymphocytic Leukemia" (4 trials), "Metastatic Breast Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials) and "Multiple Myeloma" (3 trials). Many other conditions were trialed in "Clinique Saint-Pierre" in a lesser frequency.

Most popular intervention types in "Clinique Saint-Pierre" are "Drug" (73 trials), "Other" (15 trials), "Biological" (6 trials), "Procedure" (6 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Rituximab" (7 trials), "Abemaciclib" (3 trials), "Carboplatin" (3 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Clinique Saint-Pierre" are 79 trials for "All" genders, 11 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Clinique Saint-Pierre". undefined are not yet recruiting, 8 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Clinique Saint-Pierre, 1 suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Clinique Saint-Pierre, 6 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 5 trials that are defined as “Not Applicable".